{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:23:39Z","timestamp":1789565019345,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejpb.2026.115064","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:09:57Z","timestamp":1775059797000},"page":"115064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Investigation of baicalin, baicalein and low-dose sulfasalazine for orocecal transit time determination in saliva and plasma"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-2377","authenticated-orcid":false,"given":"Stefan","family":"Senekowitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9346-525X","authenticated-orcid":false,"given":"Nikolaus Alexander","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Wildgrube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-9839","authenticated-orcid":false,"given":"Philipp","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-971X","authenticated-orcid":false,"given":"Stefan","family":"Engeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-7747","authenticated-orcid":false,"given":"Werner","family":"Weitschies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-7435","authenticated-orcid":false,"given":"Michael","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115064_b0005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","article-title":"Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics","volume":"353","author":"McCoubrey","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115064_b0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00228-007-0306-4","article-title":"Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers","volume":"63","author":"Villesen","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01740660","article-title":"The effects of omeprazole-induced hypochlorhydria on absorption of theophylline from a sustained-release formulation","volume":"43","author":"De Sommers","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0020","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1248\/cpb.38.2810","article-title":"Gastrointestinal Absorption of Chlorothiazide: Evaluation of a Method using Salicylazosulfapyridine and Acetaminophen as the Marker Compounds for Determination of the Gastrointestinal Transit Time in the Dog","volume":"38","author":"Mizuta","year":"1990","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115064_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.semnuclmed.2011.10.004","article-title":"Methods for the Assessment of Small-Bowel and Colonic Transit","volume":"42","author":"Szarka","year":"2012","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejpb.2026.115064_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijpharm.2011.07.031","article-title":"In vivo imaging of drug delivery systems in the gastrointestinal tract","volume":"417","author":"Weitschies","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115064_b0035","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s10620-009-0899-9","article-title":"Wireless capsule motility: Comparison of the smartPill\u00ae GI monitoring system with scintigraphy for measuring whole gut transit","volume":"54","author":"Maqbool","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.10.022","article-title":"Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies","volume":"220","author":"Koziolek","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115064_b0045","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/BF02088056","article-title":"Lactulose hydrogen breath test in orocecal transit assessment","volume":"39","author":"Sciarretta","year":"1994","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0050","first-page":"396","article-title":"Sulfapyridine appearance in plasma after salicylazosulfapyridine","volume":"91","author":"Kellow","year":"1986","journal-title":"Another Simple Measure of Intestinal Transit, Gastroenterology"},{"key":"10.1016\/j.ejpb.2026.115064_b0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jcph.624","article-title":"Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects","volume":"56","author":"Kolbow","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0060","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/gut.30.7.978","article-title":"Comparison of orocaecal transit times assessed by the lactulose\/breath hydrogen and the sulphasalazine\/sulphapyridine methods","volume":"30","author":"Staniforth","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2026.115064_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040801","article-title":"Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug delivery Research","volume":"14","author":"Senekowitsch","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115064_b0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jcph.359","article-title":"Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: a proof of concept study in healthy subjects","volume":"55","author":"de Gunzburg","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0009-9236(95)90217-1","article-title":"Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake","volume":"57","author":"Dh\u00f4te","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1472-8206.1992.tb00134.x","article-title":"Oro-caecal transit time in man assessed by the sulfasalazine\/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine","volume":"6","author":"Dh\u00f4te","year":"1992","journal-title":"Fundam. & Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13020-020-00384-0","article-title":"Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity of Scutellaria baicalensis Georgi. and its probably potential therapeutic effects on COVID-19: a review","volume":"15","author":"Song","year":"2020","journal-title":"Chin. Med."},{"key":"10.1016\/j.ejpb.2026.115064_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107032","article-title":"Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: a comprehensive review with future perspectives","volume":"199","author":"Wang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2026.115064_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci8060104","article-title":"Neuroprotective and Cognitive Enhancement Potentials of Baicalin: a Review","volume":"8","author":"Sowndhararajan","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0100","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3748\/wjg.v28.i26.3047","article-title":"Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: a review","volume":"28","author":"Ganguly","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2026.115064_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080370","article-title":"Pharmacokinetics of B-Ring Unsubstituted Flavones","volume":"11","author":"Ancuceanu","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115064_b0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12272-013-0179-2","article-title":"Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin","volume":"37","author":"Kang","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115064_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0928-0987(02)00221-X","article-title":"Microbially triggered drug delivery to the colon","volume":"18","author":"Sinha","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0120","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1211\/0022357001777621","article-title":"Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form","volume":"52","author":"Akao","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/10286020.2011.599321","article-title":"Identification of the metabolites of baicalein in human plasma","volume":"13","author":"Guo","year":"2011","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.ejpb.2026.115064_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115853","article-title":"Identification and high-throughput quantification of baicalein and its metabolites in plasma and urine","volume":"301","author":"Wang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1211\/002235702522","article-title":"Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats","volume":"55","author":"Lai","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jep.2014.08.031","article-title":"Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects","volume":"156","author":"Li","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0145","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40261-016-0418-7","article-title":"Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in healthy Chinese Volunteers","volume":"36","author":"Pang","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejpb.2026.115064_b0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0035-1569446","article-title":"Simultaneous Determination of Baicalein and Baicalin in Human Plasma by High Performance Liquid Chromatograph-Tandem Spectrometry and its Application in a Food-effect Pharmacokinetic Study","volume":"66","author":"Pang","year":"2016","journal-title":"Drug Res. (stuttg)"},{"key":"10.1016\/j.ejpb.2026.115064_b0155","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/cts.13063","article-title":"Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy chinese subjects: a single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study","volume":"14","author":"Li","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114052","article-title":"Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy chinese subjects: a single-center, randomized, double-blind, placebo-controlled, single-dose phase I study","volume":"274","author":"Dong","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.202200121","article-title":"Qualitative and quantitative determination of the primary active components and metabolites in human plasma after oral administration of Shuanghuanglian liquid","author":"Zhang","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0170","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejpb.2018.03.011","article-title":"Low dose caffeine as a salivary tracer for the determination of gastric water emptying in fed and fasted state: a MRI validation study","volume":"127","author":"Sager","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115064_b0175","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1021\/acs.molpharmaceut.8b01320","article-title":"Combined Application of MRI and the Salivary Tracer Technique to Determine the in Vivo Disintegration Time of Immediate Release Formulation Administered to healthy, Fasted Subjects","volume":"16","author":"Sager","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115064_b0180","unstructured":"European Medicines Agency - Committee for Human Medicinal Products (CHMP), Guideline on bioanalytical method validation, (2011)."},{"key":"10.1016\/j.ejpb.2026.115064_b0185","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jpba.2005.03.034","article-title":"Stability of baicalin in biological fluids in vitro","volume":"39","author":"Xing","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115064_b0190","first-page":"2675","article-title":"Study on stability of baicalin and baicalein in Rat plasma by HPLC-ECD","volume":"33","author":"Wang","year":"2008","journal-title":"China J. Chinese Mater. Medica"},{"key":"10.1016\/j.ejpb.2026.115064_b0195","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2015.10.022","article-title":"Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies","volume":"220","author":"Koziolek","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115064_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14101999","article-title":"In Vivo Evaluation of a Gastro-Resistant HPMC-Based \u201cnext Generation Enteric\u201d Capsule","volume":"14","author":"Rump","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115064_b0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2016.03.009","article-title":"Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers","volume":"101","author":"Koziolek","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115064_b0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lfs.2005.04.072","article-title":"Absorption and enterohepatic circulation of baicalin in rats","volume":"78","author":"Xing","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1211\/0022357056244","article-title":"Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract\u2020","volume":"57","author":"Xing","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0225","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4155\/bio.12.81","article-title":"A novel UPLC-MS\/MS method for simultaneous quantification of rhein, emodin, berberine and baicalin in rat plasma and its application in a pharmacokinetic study","volume":"4","author":"Huang","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejpb.2026.115064_b0230","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1248\/bpb.b12-00850","article-title":"Baicalein 6-O-\u03b2-D-glucopyranuronoside is a main metabolite in the plasma after oral administration of baicalin, a flavone glucuronide of scutellariae radix, to rats","volume":"36","author":"Akao","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115064_b0235","first-page":"124","article-title":"Oral pharmacokinetics of baicalin, wogonoside, oroxylin a 7-O-\u03b2-d-glucuronide and their aglycones from an aqueous extract of Scutellariae Radix in the rat., J. Chromatogr. B. Analyt. Technol. Biomed","volume":"1026","author":"Cai","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0240","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/jssc.201601420","article-title":"Development and validation of a UHPLC-MS\/MS method for the simultaneous determination of five bioactive flavonoids in rat plasma and comparative pharmacokinetic study after oral administration of Xiaochaihu Tang and three compatibilities","volume":"40","author":"Bo","year":"2017","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0245","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1248\/bpb.32.2079","article-title":"Hepatic Contribution to a Marked increase in the Plasma Concentration of Baicalin after Oral Administration of its Aglycone, Baicalein, in Multidrug Resistance-Associated Protein 2-Deficient Rat","volume":"32","author":"Akao","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115064_b0250","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1208\/s12248-011-9277-6","article-title":"Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters-in vitro and in vivo evidences","volume":"13","author":"Zhang","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115064_b0255","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1128\/aem.56.7.2146-2151.1990","article-title":"Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora","volume":"56","author":"Rafii","year":"1990","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejpb.2026.115064_b0260","first-page":"19","article-title":"Separation , purification and characterization of dye degrading enzyme azoreductase from bacterial isolate","volume":"3","author":"Saranraj","year":"2014","journal-title":"Cent. Eur. J. Exp. Biol."},{"key":"10.1016\/j.ejpb.2026.115064_b0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF03216747","article-title":"Intestinal bacterial metabolism of flavonoids and its relation to some biological activities","volume":"21","author":"Kim","year":"1998","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115064_b0270","first-page":"35","article-title":"Herbal medicines are activated by intestinal microflora","volume":"8","author":"Kim","year":"2002","journal-title":"Nat. Prod. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.fitote.2011.12.019","article-title":"Pharmacokinetic study of baicalein after oral administration in monkeys","volume":"83","author":"Tian","year":"2012","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejpb.2026.115064_b0280","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1023\/B:PHAM.0000048205.02478.b5","article-title":"Enteric Excretion of Baicalein, a Flavone of Scutellariae Radix, via Glucuronidation in Rat: Involvement of Multidrug Resistance-Associated Protein 2","volume":"21","author":"Akao","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115064_b0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1248\/bpb.26.79","article-title":"Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae Radix in humans","volume":"26","author":"Lai","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115064_b0290","doi-asserted-by":"crossref","first-page":"1621S","DOI":"10.1093\/jn\/131.5.1621S","article-title":"Human Saliva as a Diagnostic Specimen","volume":"131","author":"Hofman","year":"2001","journal-title":"J. Nutr."},{"key":"10.1016\/j.ejpb.2026.115064_b0295","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/1354750X.2010.481364","article-title":"Saliva as an analytical matrix: state of the art and application for biomonitoring","volume":"15","author":"Caporossi","year":"2010","journal-title":"Biomarkers"},{"key":"10.1016\/j.ejpb.2026.115064_b0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.forsciint.2004.10.026","article-title":"Review: the physiology of saliva and transfer of drugs into saliva","volume":"150","author":"Aps","year":"2005","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.ejpb.2026.115064_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00420-014-0938-5","article-title":"Saliva as a matrix for human biomonitoring in occupational and environmental medicine","volume":"88","author":"Michalke","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.ejpb.2026.115064_b0310","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/clpt.1984.151","article-title":"Relationship between caffeine concentrations in plasma and saliva","volume":"36","author":"Zylber-Katz","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bmc.1103","article-title":"Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives","volume":"23","author":"Mullangi","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2026.115064_b0320","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/mp300250r","article-title":"Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system","volume":"9","author":"Idkaidek","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115064_b0325","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/cpt19741661052","article-title":"Pharmacokinetics of tolbutamide: Prediction by concentration in saliva","volume":"16","author":"Matin","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0330","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1749-6632.1993.tb18340.x","article-title":"Pharmacokinetic Principles of Drug distribution in Saliva","volume":"694","author":"Jusko","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejpb.2026.115064_b0335","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.1983.234","article-title":"Quinidine saliva concentrations: Absence of correlation with serum concentrations at steady state","volume":"34","author":"Narang","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0340","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/bmc.655","article-title":"Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography","volume":"20","author":"Tang","year":"2006","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2026.115064_b0345","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2011.08.023","article-title":"Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal","volume":"420","author":"Zhang","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115064_b0350","first-page":"6183","article-title":"[Determination of plasma protein binding rate of Shuganning Injection using equilibrium dialysis and UPLC-MS\/MS]., Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China","volume":"48","author":"Xiao","year":"2023","journal-title":"J. Chinese Mater. Medica"},{"key":"10.1016\/j.ejpb.2026.115064_b0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00609587","article-title":"Plasma and salivary pharmacokinetics of caffeine in man","volume":"21","author":"Newton","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115064_b0360","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00007691-199710000-00006","article-title":"Caffeine in saliva after peroral intake: Early sample collection as a possible source of error","volume":"19","author":"Biederbick","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2026.115064_b0365","doi-asserted-by":"crossref","DOI":"10.1097\/00007691-199402000-00017","article-title":"Cerebrospinal Fluid Concentrations of Caffeine following Oral Drug Administration: Correlation with Salivary and Plasma Concentrations","volume":"16","author":"Soto","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2026.115064_b0370","first-page":"78","article-title":"Binding of Sulfonamides by Plasma Proteins, Science (80-","volume":"95","author":"Davis","year":"1942","journal-title":")"},{"key":"10.1016\/j.ejpb.2026.115064_b0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0378-4347(00)81919-2","article-title":"High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites: its application for pharmacokinetic studies with salicylazosulfapyridine in man","volume":"162","author":"Fischer","year":"1979","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejpb.2026.115064_b0380","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.98.3.261","article-title":"THE PERMEABILITY OF HUMAN SWEAT GLANDS TO a SERIES OF SULFONAMIDE COMPOUNDS","volume":"98","author":"Hess","year":"1953","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejpb.2026.115064_b0385","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/00365515509134102","article-title":"The permeability of the human parotid Gland to a series of sulfonamide compounds, paraaminohippurate and inulin","volume":"7","author":"Killmann","year":"1955","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.ejpb.2026.115064_b0390","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/cpt1977226917","article-title":"Pieniaszek Jr., Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine","volume":"22","author":"Bates","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115064_b0395","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2125.1980.tb04802.x","article-title":"Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease","volume":"9","author":"Day","year":"1980","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:29:02Z","timestamp":1782822542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":79,"alternative-id":["S0939641126000858"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115064","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of baicalin, baicalein and low-dose sulfasalazine for orocecal transit time determination in saliva and plasma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115064"}}